Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Services

Stock.adobe.com

LillyDirect will now offer Alzheimer’s care.

Eli Lilly announced the addition to its digital healthcare platform, which will be able to provide both in-person and telehealth services. According to Lilly, the majority of people in the US living with Alzheimer’s have not been formally diagnosed, yet they still require access to care and services. The problems with getting formally diagnosed are expected to get worse in the coming year.

In a press release, Eli Lilly’s chief medical officer David Hyman, MD, said, “We know that early diagnosis and care can make a big difference for people living with Alzheimer's disease. By expanding this platform, we hope to help patients identify and access additional independent specialty care capacity, which can coordinate with a patient's existing care team. The addition of Alzheimer's disease to LillyDirect reaffirms our commitment to empower patients to locate the care that is right for them when they need it."

As a result of this decision, LillyDirect is partnering with Synapticure to provide the necessary independent care options. The company’s CEO, Sandra Abrevaya, said, “As a caregiver of someone with a neurodegenerative condition, I helped start Synapticure to ensure that patients receive timely and accurate diagnoses, as well as ongoing support and treatment. We are excited to be added to LillyDirect as a patient option for comprehensive telehealth services for Alzheimer's patients, especially those in rural and underserved communities. By leveraging our experienced team of clinicians and advanced telehealth capabilities, we aim to provide hope and help for patients and their families."

Aside from enhancing its digital telehealth platform, Lilly also recently announced plans to expand its manufacturing investment in the US. In February, the company announced plans to expand its US manufacturing commitments to over $50 billion spent since 2020.²

In a press release issued at the time, Lilly chair and CEO David A. Ricks said, “Lilly's optimism about the potential of our pipeline across therapeutic areas–cardiometabolic health, oncology, immunology and neuroscience–drives our unprecedented commitment to our domestic manufacturing build-out. Our confidence positions us to help reinvigorate domestic manufacturing, which will benefit hard-working American families and increase exports of medicines made in the U.S.A. This bold move reflects our commitment to stay ahead of anticipated demand for safe, high-quality, FDA-approved medicines of the future."

Ricks continued, "The Tax Cuts and Jobs Act legislation passed in 2017 during President Trump's first term in office has been foundational to Lilly's domestic manufacturing investments, and it is essential that these policies are extended this year. We believe that our investments in America and upskilling our nation's workforce will spark a significant ripple effect. For every job we create, many more will be generated, positively impacting the communities that host our innovative new sites."

Lilly’s executive vice president and president of Lilly Manufacturing Operations Edfardo Hernandez added, “To deliver on our big bets on next-generation modalities like small molecules, biologics and nucleic acid therapies, Lilly is investing in the state-of-the-art manufacturing infrastructure needed to deliver tomorrow's safe and reliable medicines. We are not just building facilities. We are creating a future where American innovation leads the world in pharmaceutical manufacturing, requiring a highly skilled workforce prepared to shape the future of health care. This is a significant step for our company, our communities and the patients we serve."

SOURCES

LillyDirect Platform Expands to Facilitate Access to Alzheimer's Disease Care. Eli Lilly and Company. March 27, 2025. https://www.prnewswire.com/news-releases/lillydirect-platform-expands-to-facilitate-access-to-alzheimers-disease-care-302412620.html

Lilly Plans to More Than Double U.S. Manufacturing Investment Since 2020 Exceeding $50 Billion. Eli Lilly and Company. February 26, 2025. Accessed March 31, 2025. https://www.prnewswire.com/news-releases/lilly-plans-to-more-than-double-us-manufacturing-investment-since-2020-exceeding-50-billion-302385372.html